Spore-forming Bacilli and Clostridia in human disease

Future Microbiology

Volumn 5, Issue 7, 2010, Pages 1109-1123

  Mallozzi, Michael ^a   Viswanathan, V K ^a   Vedantam, Gayatri ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

anthrax; Bacillus anthracis; botulism; Clostridium botulinum; Clostridium difficile; Clostridium perfringens; Clostridium tetani; gas gangrene; spore

Indexed keywords

ANTHRAX VACCINE; ANTITOXIN; BACTERIAL VACCINE; BOTULISM VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; BACTERIAL TOXIN;

ANTHRAX; BACILLACEAE INFECTION; BACILLUS; BACTERIAL SPORE; BOTULISM; CELL ADHESION; CLOSTRIDIUM; CLOSTRIDIUM INFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPOROGENESIS; TETANUS; BIOSYNTHESIS; CYTOLOGY; GRAM POSITIVE INFECTION; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; TOXICITY;

BACILLI (CLASS); BACILLUS ANTHRACIS; CLOSTRIDIA; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM TETANI; POSIBACTERIA;

BACILLUS; BACTERIAL TOXINS; CLOSTRIDIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SPORES, BACTERIAL;

EID: 77954708542     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.60     Document Type: Review

References (275)

1. The Firmicutes. In: Bergey's Manual of Systematic Bacteriology (2nd Edition). De Vos P, Garrity G, Jones D et al. (Eds). Springer, NY, USA (2009).
2. Sass AM, McKew BA, Sass H et al.: Diversity of Bacillus-like organisms isolated from deep-sea hypersaline anoxic sediments. Saline Syst. 4, 8 (2008).
3. Nicholson WL: Roles of Bacillus endospores in the environment. Cell. Mol. Life Sci. 59(3), 410-416 (2002).
4. Hong HA, To E, Fakhry S et al.: Defining the natural habitat of Bacillus spore-formers. Res. Microbiol. 160(6), 375-379 (2009).
5. Mariat D, Firmesse O, Levenez F et al.: The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 9, 123 (2009).
6. Fekety R, Kim KH, Brown D et al.: Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am. J. Med. 70(4), 906-908 (1981). (Pubitemid 11057028)
7. Gerding DN, Muto CA, Owens RC Jr: Measures to control and prevent Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl. 1), S43-S49 (2008).
8. Huang SS, Datta R, Platt R: Risk of acquiring antibiotic-resistant bacteria from prior room occupants. Arch. Intern. Med. 166(18), 1945-1951 (2006).
9. Riggs MM, Sethi AK, Zabarsky TF et al.: Asymptomatic carriers are a potential source for transmission of epidemic and non-epidemic Clostridium difficile strains among long-term care facility residents. Clin. Infect. Dis. 45(8), 992-998 (2007).
10. McFarland LV: What's lurking under the bed? Persistence and predominance of particular Clostridium difficile strains in a hospital and the potential role of environmental contamination. Infect. Control Hosp. Epidemiol. 23(11), 639-640 (2002).
11. Eichenberger P, Fujita M, Jensen ST et al.: The program of gene transcription for a single differentiating cell type during sporulation in Bacillus subtilis. PLoS Biol. 2(10), e328 (2004).
12. Zhang L, Higgins ML, Piggot PJ: The division during bacterial sporulation is symmetrically located in Sporosarcina ureae. Mol. Microbiol. 25(6), 1091-1098 (1997).
13. Klobutcher LA, Ragkousi K, Setlow P: The Bacillus subtilis spore coat provides "eat resistance" during phagocytic predation by the protozoan Tetrahymena thermophila. Proc. Natl Acad. Sci. USA 103(1), 165-170 (2006).
14. Laaberki MH, Dworkin J: Role of spore coat proteins in the resistance of Bacillus subtilis spores to Caenorhabditis elegans predation. J. Bacteriol. 190(18), 6197-6203 (2008).
15. Setlow P: Spores of Bacillus subtilis: their resistance to and killing by radiation, heat and chemicals. J. Appl. Microbiol. 101(3), 514-525 (2006).
16. Vreeland RH, Rosenzweig WD, Powers DW: Isolation of a 250 million-year-old halotolerant bacterium from a primary salt crystal. Nature 407(6806), 897-900 (2000).
17. Cano RJ, Borucki MK: Revival and identification of bacterial spores in 25- to 40-million-year-old Dominican amber. Science 268(5213), 1060-1064 (1995).
18. te Giffel MC: Spore-formers in foods and the food processing chain. Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 66(3b), 517-522 (2001).
19. Payne DN: Microbial ecology of the production process. In: Guide to Microbiological Control in Pharmaceuticals and Medical Devices. 482 (2006).
20. Boyce JM: New approaches to decontamination of rooms after patients are discharged. Infect. Control Hosp. Epidemiol. 30(6), 515-517 (2009).
21. Dubberke ER, Gerding DN, Classen D et al.: Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect. Control Hosp. Epidemiol. 29(Suppl. 1), S81-S92 (2008).
22. Russell AD: Bacterial resistance to disinfectants: present knowledge and future problems. J. Hosp. Infect. 43(Suppl.), S57-S68 (1999).
23. Gerding DN, Muto CA, Owens RC Jr: Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl. 1), S32-S42 (2008).
24. Casula G, Cutting SM: Bacillus probiotics: spore germination in the gastrointestinal tract. Appl. Environ. Microbiol. 68(5), 2344-2352 (2002).
25. Fakhry S, Sorrentini I, Ricca E et al.: Characterization of spore forming bacilli isolated from the human gastrointestinal tract. J. Appl. Microbiol. 105(6), 2178-2186 (2008).
26. Sorg JA, Sonenshein AL: Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190(7), 2505-2512 (2008).
27. Tam NK, Uyen NQ, Hong HA et al.: The intestinal life cycle of Bacillus subtilis and close relatives. J. Bacteriol. 188(7), 2692-2700 (2006).
28. Stenfors Arnesen LP, Fagerlund A, Granum PE: From soil to gut: Bacillus cereus and its food poisoning toxins. FEMS Microbiol. Rev. 32(4), 579-606 (2008).
29. Lund BM: Foodborne disease due to Bacillus and Clostridium species. Lancet. 336(8721), 982-986 (1990).
30. Cybulski RJ Jr, Sanz P, Alem F et al.: Four superoxide dismutases contribute to Bacillus anthracis virulence and provide spores with redundant protection from oxidative stress. Infect. Immun. 77(1), 274-285 (2009).
31. Ruthel G, Ribot WJ, Bavari S et al.: Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J. Infect. Dis. 189(7), 1313-1316 (2004).
32. Weaver J, Kang TJ, Raines KW et al.: Protective role of Bacillus anthracis exosporium in macrophage-mediated killing by nitric oxide. Infect. Immun. 75(8), 3894-3901 (2007).
33. Guidi-Rontani C, Levy M, Ohayon H et al.: Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol. Microbiol. 42(4), 931-938 (2001).
34. Ramarao N, Lereclus D: The InhA1 metalloprotease allows spores of the B. cereus group to escape macrophages. Cell Microbiol. 7(9), 1357-1364 (2005).
35. Banks DJ, Barnajian M, Maldonado-Arocho FJ et al.: Anthrax toxin receptor 2 mediates Bacillus anthracis killing of macrophages following spore challenge. Cell Microbiol. 7(8), 1173-1185 (2005).
36. Andersson A, Ronner U, Granum PE: What problems does the food industry have with the spore-forming pathogens Bacillus cereus and Clostridium perfringens? Int. J. Food Microbiol. 28(2), 145-155 (1995).
37. Dettenkofer M, Block C: Hospital disinfection: efficacy and safety issues. Curr. Opin. Infect. Dis. 18(4), 320-325 (2005).
38. Haberer K: Cleaning and disinfection in the control of pharmaceutical cleanrooms. In: Validation of Pharmaceutical Processes. Agalloco J, Carleton FJ, Informa Heathcare, NY, USA, 303 (2007).
39. Altman SJ, McGrath LK, Souza CA et al.: Integration and decontamination of Bacillus cereus in Pseudomonas fluorescens biofilms. J. Appl. Microbiol. 107(1), 287-299 (2009).
40. Barbut F, Menuet D, Verachten M et al.: Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of Clostridium difficile spores. Infect. Control Hosp. Epidemiol. 30(6), 507-514 (2009).
41. Beekes M, Lemmer K, Thomzig A et al.: Fast, broad-range disinfection of bacteria, fungi, viruses and prions. J. Gen. Virol. 91(Pt 2), 580-589 (2010).
42. Edmonds JM: Efficient methods for large-area surface sampling of sites contaminated with pathogenic microorganisms and other hazardous agents: current state, needs, and perspectives. Appl. Microbiol. Biotechnol. 84(5), 811-816 (2009).
43. Kida N: Sporicidal activity of an improved iodide formulation and suggestions regarding the biological safety cabinet. Biocontrol Sci. 14(2), 77-82 (2009).
44. Luksiene Z, Buchovec I, Paskeviciute E: Inactivation of food pathogen Bacillus cereus by photosensitization in vitro and on the surface of packaging material. J. Appl. Microbiol. 107(6), 2037-2046 (2009).
45. Moat J, Cargill J, Shone J et al.: Application of a novel decontamination process using gaseous ozone. Can. J. Microbiol. 55(8), 928-933 (2009).
46. Rogers MA, Blumberg N, Saint S et al.: Hospital variation in transfusion and infection after cardiac surgery: a cohort study. BMC Med. 7, 37 (2009).
47. La Duc MT, Satomi M, Venkateswaran K: Bacillus odysseyi sp. nov., a round-spore-forming bacillus isolated from the Mars Odyssey spacecraft. Int. J. Syst. Evol. Microbiol. 54(Pt 1), 195-201 (2004).
48. Chen G, Driks A, Tawfiq K et al.: Bacillus anthracis and Bacillus subtilis spore surface properties and transport. Colloids Surf. B Biointerfaces 76(2), 512-518. (2010).
49. Bowen WR, Fenton AS, Lovitt RW et al.: The measurement of Bacillus mycoides spore adhesion using atomic force microscopy, simple counting methods, and a spinning disk technique. Biotechnol. Bioeng. 79(2), 170-179 (2002).
50. Andersson A, Granum PE, Ronner U: The adhesion of Bacillus cereus spores to epithelial cells might be an additional virulence mechanism. Int. J. Food Microbiol. 39(1-2), 93-99 (1998).
51. Bozue J, Moody KL, Cote CK et al.: Bacillus anthracis spores of the bclA mutant exhibit increased adherence to epithelial cells, fibroblasts, and endothelial cells but not to macrophages. Infect. Immun. 75(9), 4498-4505 (2007).
52. Russell BH, Vasan R, Keene DR et al.: Potential dissemination of Bacillus anthracis utilizing human lung epithelial cells. Cell Microbiol. 10(4), 945-957 (2008).
53. Russell BH, Vasan R, Keene DR et al.: Bacillus anthracis internalization by human fibroblasts and epithelial cells. Cell Microbiol. 9(5), 1262-1274 (2007).
54. Oliva C, Turnbough CL Jr, Kearney JF: CD14-Mac-1 interactions in Bacillus anthracis spore internalization by macrophages. Proc. Natl Acad. Sci. USA 106(33), 13957-13962 (2009).
55. Oliva CR, Swiecki MK, Griguer CE et al.: The integrin Mac-1 (CR3) mediates internalization and directs Bacillus anthracis spores into professional phagocytes. Proc. Natl Acad. Sci. USA 105(4), 1261-1266 (2008).
56. Paredes-Sabja D, Setlow P, Sarker MR: SleC is essential for cortex peptidoglycan hydrolysis during germination of spores of the pathogenic bacterium Clostridium perfringens. J. Bacteriol. 191(8), 2711-2720 (2009).
57. Carr KA, Lybarger SR, Anderson EC et al.: The role of Bacillus anthracis germinant receptors in germination and virulence. Mol. Microbiol. 75(2), 365-375 (2010).
58. Burns DA, Heap JT, Minton NP: SleC is essential for germination of Clostridium difficile spores in nutrient-rich medium supplemented with the bile salt taurocholate. J. Bacteriol. 192(3), 657-664 (2009).
59. Heffron JD, Orsburn B, Popham DL: Roles of germination-specific lytic enzymes CwlJ and SleB in Bacillus anthracis. J. Bacteriol. 191(7), 2237-2247 (2009).
60. Bergman NH, Anderson EC, Swenson EE et al.: Transcriptional profiling of Bacillus anthracis during infection of host macrophages. Infect. Immun. 75(7), 3434-3444 (2007).
61. Cote CK, DiMezzo TL, Banks DJ et al.: Early interactions between fully virulent Bacillus anthracis and macrophages that influence the balance between spore clearance and development of a lethal infection. Microbes Infect. 10(6), 613-619 (2008).
62. Guidi-Rontani C, Weber-Levy M, Labruyere E et al.: Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol. 31(1), 9-17 (1999).
63. Guidi-Rontani C: The alveolar macrophage: the Trojan horse of Bacillus anthracis. Trends Microbiol. 10(9), 405-409 (2002).
64. Abramova FA, Grinberg LM, Yampolskaya OV et al.: Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc. Natl Acad. Sci. USA 90(6), 2291-2294 (1993).
65. Baillie L, Hibbs S, Tsai P et al.: Role of superoxide in the germination of Bacillus anthracis endospores. FEMS Microbiol. Lett. 245(1), 33-38 (2005).
66. Shatalin K, Gusarov I, Avetissova E et al.: Bacillus anthracis-derived nitric oxide is essential for pathogen virulence and survival in macrophages. Proc. Natl Acad. Sci. USA 105(3), 1009-1013 (2008).
67. Chung MC, Popova TG, Jorgensen SC et al.: Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. J. Biol. Chem. 283(15), 9531-9542 (2008).
68. Kastrup CJ, Boedicker JQ, Pomerantsev AP et al.: Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'. Nat. Chem. Biol. 4(12), 742-750 (2008).
69. Schade VL, Roukis TS, Haque MM: Clostridium septicum necrotizing fasciitis of the forefoot secondary to adenocarcinoma of the colon: case report and review of the literature. J. Foot Ankle Surg. 49(2), e1-e8 (2010).
70. Taylor JM, Sutherland AD, Aidoo KE et al.: Heat-stable toxin production by strains of Bacillus cereus, Bacillus firmus, Bacillus megaterium, Bacillus simplex and Bacillus licheniformis. FEMS Microbiol. Lett. 242(2), 313-317 (2005).
71. Banks DJ, Ward SC, Bradley KA: New insights into the functions of anthrax toxin. Expert Rev. Mol. Med. 8(7), 1-18 (2006).
72. Barth H, Aktories K, Popoff MR et al.: Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol. Mol. Biol. Rev. 68(3), 373-402 (2004).
73. Boquet P, Munro P, Fiorentini C et al.: Toxins from anaerobic bacteria: specificity and molecular mechanisms of action. Curr. Opin. Microbiol. 1(1), 66-74 (1998).
74. Hatheway CL: Toxigenic Clostridia. Clin. Microbiol. Rev. 3(1), 66-98 (1990).
75. de Maagd RA, Bravo A, Berry C et al.: Structure, diversity, and evolution of protein toxins from spore-forming entomopathogenic bacteria. Annu. Rev. Genet. 37, 409-433 (2003).
76. Voth DE, Ballard JD: Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18(2), 247-263 (2005).
77. Bergey DH, Etris S: Immunization of humans with alum precipitated tetanus toxoid. Am. J. Public Health Nations Health 24(6 Pt 1), 582-586 (1934).
78. Davis GG: VI. Two cases of recovery from traumatic tetanus after the use of antitoxin. Ann. Surg. 28(2), 237-243 (1898).
79. Dembek ZF, Smith LA, Rusnak JM: Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med. Public Health Prep. 1(2), 122-134 (2007).
80. Smith LA: Botulism and vaccines for its prevention. Vaccine. 27(Suppl. 4), D33-D39 (2009).
81. Tournier JN, Ulrich RG, Quesnel-Hellmann A et al.: Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev. Anti Infect. Ther. 7(2), 219-236 (2009).
82. Auerbach S, Wright GG: Studies on immunity in anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis. J. Immunol. 75(2), 129-133 (1955).
83. Ward MK, McGann VG, Hogge AL Jr et al.: Studies on anthrax infections in immunized guinea pigs. J. Infect. Dis. 115, 59-67 (1965).
84. Alexander CJ, Citron DM, Brazier JS et al.: Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens. J. Clin. Microbiol. 33(12), 3209-3215 (1995).
85. Alvarez Z, Abel-Santos E: Potential use of inhibitors of bacteria spore germination in the prophylactic treatment of anthrax and Clostridium difficile-associated disease. Expert Rev. Anti Infect. Ther. 5(5), 783-792 (2007).
86. Coia JE: What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile? Int. J. Antimicrob. Agents 33(Suppl. 1), S9-S12 (2009).
87. Cohen MB: Clostridium difficile infections: emerging epidemiology and new treatments. J. Pediatr. Gastroenterol. Nutr. 48(Suppl. 2), S63-S65 (2009).
88. Friedlander AM, Little SF: Advances in the development of next-generation anthrax vaccines. Vaccine. 27(Suppl. 4), D28-D32 (2009).
89. Bouzianas DG: Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Expert Rev. Anti Infect. Ther. 5(4), 665-684 (2007).
90. McKevitt MT, Bryant KM, Shakir SM et al.: Effects of endogenous d-alanine synthesis and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections. Infect. Immun. 75(12), 5726-5734 (2007).
91. Akoachere M, Squires RC, Nour AM et al.: Identification of an in vivo inhibitor of Bacillus anthracis spore germination. J. Biol. Chem. 282(16), 12112-12118 (2007).
92. Popov SG, Popova TG, Hopkins S et al.: Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect. Dis. 5(1), 25 (2005).
93. Shoop WL, Xiong Y, Wiltsie J et al.: Anthrax lethal factor inhibition. Proc. Natl Acad. Sci. USA 102(22), 7958-7963 (2005).
94. Roxas-Duncan V, Enyedy I, Montgomery VA et al.: Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob. Agents Chemother. 53(8), 3478-3486 (2009).
95. Tonello F, Montecucco C: The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol. Aspects Med. 30(6), 431-438 (2009).
96. Cegelski L, Marshall GR, Eldridge GR et al.: The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 6(1), 17-27 (2008).
97. Coico R, Kowalik T, Quarles J, Stevenson B, Taylor R: Current Protocols in Microbiology. John Wiley & Sons, Inc., Hoboken, NJ, USA (2005).
98. Jones MB, Jani R, Ren D et al.: Inhibition of Bacillus anthracis growth and virulence-gene expression by inhibitors of quorum-sensing. J. Infect. Dis. 191(11), 1881-1888 (2005).
99. Han X, Lu C: Biological activity and identification of a peptide inhibitor of LuxS from Streptococcus suis serotype 2. FEMS Microbiol. Lett. 294(1), 16-23 (2009).
100. Kim C, Kim J, Park HY et al.: Furanone derivatives as quorum-sensing antagonists of Pseudomonas aeruginosa. Appl. Microbiol. Biotechnol. 80(1), 37-47 (2008).
101. Otto M: Quorum-sensing control in staphylococci - a target for antimicrobial drug therapy? FEMS Microbiol. Lett. 241(2), 135-141 (2004).
102. Rasch M, Buch C, Austin B et al.: An inhibitor of bacterial quorum sensing reduces mortalities caused by vibriosis in rainbow trout (Oncorhynchus mykiss, Walbaum). Syst. Appl. Microbiol. 27(3), 350-359 (2004).
103. Balaban N, Giacometti A, Cirioni O et al.: Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J. Infect. Dis. 187(4), 625-630 (2003).
104. Lee AS, Song KP: LuxS/autoinducer-2 quorum sensing molecule regulates transcriptional virulence gene expression in Clostridium difficile. Biochem. Biophys. Res. Commun. 335(3), 659-666 (2005).
105. Vidal JE, Chen J, Li J et al.: Use of an EZ-Tn5-based random mutagenesis system to identify a novel toxin regulatory locus in Clostridium perfringens strain 13. PLoS ONE 4(7), e6232 (2009).
106. Ohtani K, Yuan Y, Hassan S et al.: Virulence gene regulation by the agr system in Clostridium perfringens. J. Bacteriol. 191(12), 3919-3927 (2009).
107. Bouillaut L, Perchat S, Arold S et al.: Molecular basis for group-specific activation of the virulence regulator PlcR by PapR heptapeptides. Nucleic Acids Res. 36(11), 3791-3801 (2008).
108. Fabbri A, Travaglione S, Falzano L et al.: Bacterial protein toxins: current and potential clinical use. Curr. Med. Chem. 15(11), 1116-1125 (2008).
109. Johnson EA: Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53, 551-575 (1999).
110. Popoff MR, Bouvet P: Clostridial toxins. Future Microbiol. 4, 1021-1064 (2009).
111. Cheng CM, Chen JS, Patel RP: Unlabeled uses of botulinum toxins: a review, part 2. Am. J. Health Syst. Pharm. 63(3), 225-232 (2006).
112. Cheng CM, Chen JS, Patel RP: Unlabeled uses of botulinum toxins: a review, part 1. Am. J. Health Syst. Pharm. 63(2), 145-152 (2006).
113. Duesbery NS, Webb CP, Leppla SH et al.: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280(5364), 734-737 (1998).
114. Bodart JF, Chopra A, Liang X et al.: Anthrax, MEK and cancer. Cell Cycle 1(1), 10-15 (2002).
115. Alfano RW, Leppla SH, Liu S et al.: Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis. Mol. Cancer Res. 7(4), 452-461 (2009).
116. Duesbery NS, Resau J, Webb CP et al.: Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc. Natl Acad. Sci. USA 98(7), 4089-4094 (2001).
117. Dang LH, Bettegowda C, Agrawal N et al.: Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol. Ther. 3(3), 326-337 (2004).
118. Parker RC, Plummer HC, Siebenmann CO, Chapman MG: Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc. Soc. Exp. Biol. Med. 66(2), 461-467 (1947).
119. Wei MQ, Mengesha A, Good D et al.: Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett. 259(1), 16-27 (2008).
120. Van Mellaert L, Barbe S, Anne J: Clostridium spores as anti-tumour agents. Trends Microbiol. 14(4), 190-196 (2006).
121. Li Z, Fallon J, Mandeli J et al.: A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J. Natl Cancer Inst. 100(19), 1389-1400 (2008).
122. Frankel AE, Kuo SR, Dostal D et al.: Pathophysiology of anthrax. Front. Biosci. 14, 4516-4524 (2009).
123. Koch R: The etiology of anthrax, based on the life history of Bacillus anthracis. Beitr. Biol. Pflanz 2, 277-310 (1876).
124. Bekemeyer WB, Zimmerman GA: Life-threatening complications associated with Bacillus cereus pneumonia. Am. Rev. Respir. Dis. 131(3), 466-469 (1985).
125. Carbone JE, Stauffer JL: Bacillus cereus pleuropulmonary infection in a normal host. West J. Med. 143(5), 676-677 (1985).
126. Chhabra S, Kunimoto DY, Kazi L et al.: Endophthalmitis after open globe injury: microbiologic spectrum and susceptibilities of isolates. Am. J. Ophthalmol. 142(5), 852-854 (2006).
127. Drobniewski FA: Bacillus cereus and related species. Clin. Microbiol. Rev. 6(4), 324-338 (1993).
128. Frankard J, Li R, Taccone F et al.: Bacillus cereus pneumonia in a patient with acute lymphoblastic leukemia. Eur. J. Clin. Microbiol. Infect. Dis. 23(9), 725-728 (2004).
129. Matsumoto S, Suenaga H, Naito K et al.: Management of suspected nosocomial infection: an audit of 19 hospitalized patients with septicemia caused by Bacillus species. Jpn J. Infect. Dis. 53(5), 196-202 (2000).
130. Meredith FT, Fowler VG, Gautier M et al.: Bacillus cereus necrotizing cellulitis mimicking clostridial myonecrosis: case report and review of the literature. Scand. J. Infect. Dis. 29(5), 528-529 (1997).
131. Miller JJ, Scott IU, Flynn HW Jr et al.: Endophthalmitis caused by Bacillus species. Am. J. Ophthalmol. 145(5), 883-888 (2008).
132. Schricker ME, Thompson GH Schreiber JR: Osteomyelitis due to Bacillus cereus in an adolescent: case report and review. Clin. Infect. Dis. 18(6), 863-867 (1994).
133. Banerjee C, Bustamante CI, Wharton R et al.: Bacillus infections in patients with cancer. Arch. Intern. Med. 148(8), 1769-1774 (1988).
134. Castagnola E, Conte M, Venzano P et al.: Broviac catheter-related bacteraemias due to unusual pathogens in children with cancer: case reports with literature review. J. Infect. 34(3), 215-218 (1997).
135. Gatermann S, Mitusch R, Djonlagic H et al.: Endocarditis caused by Bacillus circulans. Infection 19(6), 445 (1991).
136. Goudswaard WB, Dammer MH, Hol C: Bacillus circulans infection of a proximal interphalangeal joint after a clenched-fist injury caused by human teeth. Eur. J. Clin. Microbiol. Infect. Dis. 14(11), 1015-1016 (1995).
137. Krause A, Gould FK, Forty J: Prosthetic heart valve endocarditis caused by Bacillus circulans. J. Infect. 39(2), 160-162 (1999).
138. Logan NA, Old DC, Dick HM: Isolation of Bacillus circulans from a wound infection. J. Clin. Pathol. 38(7), 838-839 (1985).
139. Tandon A, Tay-Kearney ML, Metcalf C et al.: Bacillus circulans endophthalmitis. Clin. Experiment. Ophthalmol. 29(2), 92-93 (2001).
140. Wilde AH Ruth JT: Two-stage reimplantation in infected total knee arthroplasty. Clin. Orthop. Relat. Res. (236), 23-35 (1988).
141. Takeshita S, Matsumoto T, Nishio E et al.: [A case suspected to be the bacteremia due to opportunistic infection by Bacillus coagulans, which was difficult to identify, at the time of isolation (author's transl)]. Rinsho Byori. 28(3), 277-280 (1980).
142. Hong T, Heibler N, Tang YW: "Bacillus hackensackii" sp. nov., a novel carbon dioxide sensitive bacterium isolated from blood culture. Diagn. Microbiol. Infect. Dis. 45(2), 143-147 (2003).
143. Blue SR, Singh VR, Saubolle MA: Bacillus licheniformis bacteremia: five cases associated with indwelling central venous catheters. Clin. Infect. Dis. 20(3), 629-633 (1995).
144. Hannah WN Jr, Ender PT: Persistent Bacillus licheniformis bacteremia associated with an international injection of organic drain cleaner. Clin. Infect. Dis. 29(3), 659-661 (1999).
145. Jones BL, Hanson MF, Logan NA: Isolation of Bacillus licheniformis from a brain abscess following a penetrating orbital injury. J. Infect. 24(1), 103-104 (1992).
146. Lepine A, Michel F, Nicaise C et al.: Bacillus licheniformis septicemia in a very-low-birth-weight neonate: a case report. Infection 37(2), 156-158 (2009).
147. Longo F, Pavone E, Califano L: About a case of parotid gland abscess by Bacillus licheniformis. Br. J. Plast. Surg. 56(4), 424-426 (2003).
148. Ozkocaman V, Ozcelik T, Ali R et al.: Bacillus spp. among hospitalized patients with haematological malignancies: clinical features, epidemics and outcomes. J. Hosp. Infect. 64(2), 169-176 (2006).
149. Santini F, Borghetti V, Amalfitano G et al.: Bacillus licheniformis prosthetic aortic valve endocarditis. J. Clin. Microbiol. 33(11), 3070-3073 (1995).
150. Tabbara KF, Tarabay N: Bacillus licheniformis corneal ulcer. Am. J. Ophthalmol. 87(5), 717-719 (1979).
151. Thurn JR, Goodman JL: Post-traumatic ophthalmitis due to Bacillus licheniformis. Am. J. Med. 85(5), 708-710 (1988).
152. Young RF, Yoshimori RN, Murray DL et al.: Postoperative neurosurgical infections due to bacillus species. Surg. Neurol. 18(4), 271-273 (1982).
153. Ramos-Esteban JC, Servat JJ, Tauber S et al.: Bacillus megaterium delayed onset lamellar keratitis after LASIK. J. Refract. Surg. 22(3), 309-312 (2006).
154. Na JS, Kim TH, Kim HS et al.: Liver abscess and sepsis with Bacillus pantothenticus in an immunocompetent patient: a first case report. World J. Gastroenterol. 15(42), 5360-5363 (2009).
155. Bentur HN, Dalzell AM, Riordan FA: Central venous catheter infection with Bacillus pumilus in an immunocompetent child: a case report. Ann. Clin. Microbiol. Antimicrob. 6, 12 (2007).
156. From C, Hormazabal V, Granum PE: Food poisoning associated with pumilacidin-producing Bacillus pumilus in rice. Int. J. Food Microbiol. 115(3), 319-324 (2007).
157. Bulfoni A, Schiavon I: [Hospital load of bacterial intestinal infections]. Minerva Gastroenterol. Dietol. 44(2), 79-82 (1998).
158. Baltch AL, Buhac I, Agrawal A et al.: Bacteremia after upper gastrointestinal endoscopy. Arch. Intern. Med. 137(5), 594-597 (1977).
159. Oggioni MR, Pozzi G, Valensin PE et al.: Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J. Clin. Microbiol. 36(1), 325-326 (1998).
160. Richard V, Van der Auwera P, Snoeck R et al.: Nosocomial bacteremia caused by Bacillus species. Eur. J. Clin. Microbiol. Infect. Dis. 7(6), 783-785 (1988).
161. Stickel F, Droz S, Patsenker E et al.: Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J. Hepatol. 50(1), 111-117 (2009).
162. Callegan MC, Cochran DC, Kane ST et al.: Virulence factor profiles and antimicrobial susceptibilities of ocular bacillus isolates. Curr. Eye Res. 31(9), 693-702 (2006).
163. Damgaard PH, Granum PE, Bresciani J et al.: Characterization of Bacillus thuringiensis isolated from infections in burn wounds. FEMS Immunol. Med. Microbiol. 18(1), 47-53 (1997).
164. Ghelardi E, Celandroni F, Salvetti S et al.: Bacillus thuringiensis pulmonary infection: critical role for bacterial membrane-damaging toxins and host neutrophils. Microbes Infect. 9(5), 591-598 (2007).
165. Helgason E, Caugant DA, Olsen I et al.: Genetic structure of population of Bacillus cereus and B. thuringiensis isolates associated with periodontitis and other human infections. J. Clin. Microbiol. 38(4), 1615-1622 (2000).
166. Jackson SG, Goodbrand RB, Ahmed R et al.: Bacillus cereus and Bacillus thuringiensis isolated in a gastroenteritis outbreak investigation. Lett. Appl. Microbiol. 21(2), 103-105 (1995).
167. Kuroki R, Kawakami K, Qin L et al.: Nosocomial bacteremia caused by biofilm-forming Bacillus cereus and Bacillus thuringiensis. Intern. Med. 48(10), 791-796 (2009).
168. Samples JR, Buettner H: Ocular infection caused by a biological insecticide. J. Infect. Dis. 148(3), 614 (1983).
169. Samples JR, Buettner H: Corneal ulcer caused by a biologic insecticide (Bacillus thuringiensis). Am. J. Ophthalmol. 95(2), 258-260 (1983).
170. Noskin GA, Suriano T, Collins S et al.: Paenibacillus macerans pseudobacteremia resulting from contaminated blood culture bottles in a neonatal intensive care unit. Am. J. Infect. Control 29(2), 126-129 (2001).
171. Ko KS, Kim YS, Lee MY et al.: Paenibacillus konsidensis sp. nov., isolated from a patient. Int. J. Syst. Evol. Microbiol. 58(Pt 9), 2164-2168 (2008).
172. Teng JL, Woo PC, Leung KW et al.: Pseudobacteraemia in a patient with neutropenic fever caused by a novel paenibacillus species: Paenibacillus hongkongensis sp. nov. Mol. Pathol. 56(1), 29-35 (2003).
173. Warren YA, Tyrrell KL, Citron DM et al.: Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. isolated from human clinical infections. J. Clin. Microbiol. 44(7), 2416-2422 (2006).
174. Citron DM, Goldstein EJ, Merriam CV et al.: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol. 45(9), 2819-2828 (2007).
175. Carlier JP, Manich M, Loiez C et al.: First isolation of Clostridium amygdalinum from a patient with chronic osteitis. J. Clin. Microbiol. 44(10), 3842-3844 (2006).
176. Jonsson S, Clarridge J, Young EJ: Necrotizing pneumonia and empyema caused by Bacillus cereus and Clostridium bifermentans. Am. Rev. Respir. Dis. 127(3), 357-359 (1983).
177. Kolander SA, Cosgrove EM, Molavi A: Clostridial endocarditis. Report of a case caused by Clostridium bifermentans and review of the literature. Arch. Intern. Med. 149(2), 455-456 (1989).
178. Moyano R, Gomez-Mateos JM, Lozano de Leon F et al.: Clostridium bifermentans: an exceptional agent of endocarditis. Clin. Infect. Dis. 18(5), 837 (1994).
179. Nachman S, Kaul A, Li KI et al.: Liver abscess caused by Clostridium bifermentans following blunt abdominal trauma. J. Clin. Microbiol. 27(5), 1137-1138 (1989).
180. Nolan B, Leers WD, Schatzker J: Septic arthritis of the knee due to Clostridium bifermentans. Report of a case. J. Bone Joint Surg. Am. 54(6), 1275-1278 (1972).
181. Pencek TL, Burchiel KJ: Delayed brain abscess related to a retained foreign body with culture of Clostridium bifermentans. Case report. J. Neurosurg. 64(5), 813-815 (1986).
182. Rechtman DJ, Nadler JP: Abdominal abscess due to Cardiobacterium hominis and Clostridium bifermentans. Rev. Infect. Dis. 13(3), 418-419 (1991).
183. Rehany U, Dorenboim Y, Lefler E et al.: Clostridium bifermentans panophthalmitis after penetrating eye injury. Ophthalmology 101(5), 839-842 (1994).
184. Scanlan DR, Smith MA, Isenberg HD et al.: Clostridium bifermentans bacteremia with metastatic osteomyelitis. J. Clin. Microbiol. 32(11), 2867-2868 (1994).
185. Finegold SM, Song Y, Liu C et al.: Clostridium clostridioforme: a mixture of three clinically important species. Eur. J. Clin. Microbiol. Infect. Dis. 24(5), 319-324 (2005).
186. Song Y, Liu C, Molitoris DR et al.: Clostridium bolteae sp. nov., isolated from human sources. Syst. Appl. Microbiol. 26(1), 84-89 (2003).
187. van Ermengem E: Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift fur Hygiene und Infektionskrankheiten 26: 1-56, 1897. Rev. Infect. Dis. 1(4), 701-719 (1979).
188. Gardner EM, Kestler M, Beieler A et al.: Clostridium butyricum sepsis in an injection drug user with an indwelling central venous catheter. J. Med. Microbiol. 57(Pt 2), 236-239 (2008).
189. Fenicia L, Franciosa G, Pourshaban M et al.: Intestinal toxemia botulism in two young people, caused by Clostridium butyricum type E. Clin. Infect. Dis. 29(6), 1381-1387 (1999).
190. Sturm R, Staneck JL, Stauffer LR et al.: Neonatal necrotizing enterocolitis associated with penicillin-resistant, toxigenic Clostridium butyricum. Pediatrics 66(6), 928-931 (1980).
191. Gucalp R, Motyl M, Carlisle P et al.: Clostridium cadaveris bacteremia in the immunocompromised host. Med. Pediatr. Oncol. 21(1), 70-72 (1993).
192. Leung J, Sasson M, Patel SR et al.: Clostrium cadaveris intra-peritoneal abscess. Am. J. Gastroenterol. 104(10), 2635-2636 (2009).
193. Morshed S, Malek F, Silverstein RM et al.: Clostridium cadaveris septic arthritis after total hip arthroplasty in a metastatic breast cancer patient. J. Arthroplasty 22(2), 289-292 (2007).
194. Poduval RD, Mohandas R, Unnikrishnan D et al.: Clostridium cadaveris bacteremia in an immunocompetent host. Clin. Infect. Dis. 29(5), 1354-1355 (1999).
195. Schade RP, Van Rijn M, Timmers HJ et al.: Clostridium cadaveris bacteraemia: two cases and review. Scand. J. Infect. Dis. 38(1), 59-62 (2006).
196. Stolk-Engelaar V, Verwiel J, Bongaerts G et al.: Pleural empyema due to Clostridium difficile and Clostridium cadaveris. Clin. Infect. Dis. 25(1), 160 (1997).
197. Wort AJ, Ozere RL: Characteristics of a strain of Clostridium carnis causing septicaemia in a young infant. J. Clin. Pathol. 29(11), 1011-1013 (1976).
198. Glazunova OO, Raoult D, Roux V: First identification of Clostridium celerecrescens in liquid drained from an abscess. J. Clin. Microbiol. 43(6), 3007-3008 (2005).
199. Nagano N, Isomine S, Kato H et al.: Human fulminant gas gangrene caused by Clostridium chauvoei. J. Clin. Microbiol. 46(4), 1545-1547 (2008).
200. Borrega-Garcia P, Jimenez-Mejias ME, Chinchon I et al.: [A retrorectal paravertebral abscess and meningitis due to Clostridium clostridioforme]. Med. Clin. (Barc.) 102(7), 279 (1994).
201. Garbarini-Maywood C, Mulligan ME: Ventriculoperitoneal shunt infection due to anaerobic and facultative bacteria: case report. Clin. Infect. Dis. 20(Suppl. 2), S240-S241 (1995).
202. Goldstein EJ, Citron DM, Merriam CV et al.: General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin. Infect. Dis. 35(Suppl. 1), S119-S125 (2002).
203. Allen SD, Emery CL, Lyerly DM: Clostridium. In: Manual of Clinical Microbiology. Marray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH (Eds). American Society for Microbiology, 835-856 (2003).
204. Bartlett JG, Chang TW, Gurwith M et al.: Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 298(10), 531-534 (1978). (Pubitemid 8295586)
205. Bartlett JG, Moon N, Chang TW et al.: Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 75(5), 778-782 (1978).
206. George RH, Symonds JM, Dimock F et al.: Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br. Med. J. 1(6114), 695 (1978).
207. Libby DB, Bearman G: Bacteremia due to Clostridium difficile-review of the literature. Int. J. Infect. Dis. 13(5), e305-e309 (2009).
208. O'Connor JR, Johnson S, Gerding DN: Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136(6), 1913-1924 (2009).
209. Eastwood C: Clostridium difficile from a peri-anal abscess. J. Infect. 2(4), 375 (1980).
210. Wolf LE, Gorbach SL, Granowitz EV: Extraintestinal Clostridium difficile: 10 years' experience at a tertiary-care hospital. Mayo Clin. Proc. 73(10), 943-947 (1998).
211. McCarthy J, Stingemore N: Clostridium difficile infection of a prosthetic joint presenting 12 months after antibiotic-associated diarrhoea. J. Infect. 39(1), 94-96 (1999).
212. Lazzarini L, Conti E, Ditri L et al.: Clostridial orthopedic infections: case reports and review of the literature. J. Chemother. 16(1), 94-97 (2004).
213. Marculescu CE, Berbari EF, Cockerill FR 3rd et al.: Unusual aerobic and anaerobic bacteria associated with prosthetic joint infections. Clin. Orthop. Relat. Res. 451, 55-63 (2006).
214. Birnbaum J, Bartlett JG, Gelber AC: Clostridium difficile: an under-recognized cause of reactive arthritis? Clin. Rheumatol. 27(2), 253-255 (2008).
215. Gorbach SL, Thadepalli H: Isolation of Clostridium in human infections: evaluation of 114 cases. J. Infect. Dis. 131(Suppl.), S81-S85 (1975).
216. Hausmann R, Albert F, Geissdorfer W et al.: Clostridium fallax associated with sudden death in a 16-year-old boy. J. Med. Microbiol. 53(Pt 6), 581-583 (2004).
217. Jiang W, Abrar S, Romagnoli M et al.: Clostridium glycolicum wound infections: case reports and review of the literature. J. Clin. Microbiol. 47(5), 1599-1601 (2009).
218. Van Leer C, Wensing AM, van Leeuwen JP et al.: Clostridium glycolicum isolated from a patient with otogenic brain abscesses. J. Clin. Microbiol. 47(2), 511-513 (2009).
219. Drancourt M, Berger P, Raoult D: Systematic 16S rRNA gene sequencing of atypical clinical isolates identified 27 new bacterial species associated with humans. J. Clin. Microbiol. 42(5), 2197-2202 (2004).
220. Elsayed S, Zhang K: Human infection caused by Clostridium hathewayi. Emerg. Infect. Dis. 10(11), 1950-1952 (2004).
221. Linscott AJ, Flamholtz RB, Shukla D et al.: Fatal septicemia due to Clostridium hathewayi and Campylobacter hominis. Anaerobe 11(1-2), 97-98 (2005).
222. Woo PC, Lau SK, Woo GK et al.: Bacteremia due to Clostridium hathewayi in a patient with acute appendicitis. J. Clin. Microbiol. 42(12), 5947-5949 (2004).
223. Alfa MJ, Robson D, Davi M et al.: An outbreak of necrotizing enterocolitis associated with a novel clostridium species in a neonatal intensive care unit. Clin. Infect. Dis. 35(Suppl. 1), S101-S105 (2002).
224. Abdel-Haq NM, Chearskul P, Salimnia H et al.: Clostridial liver abscess following blunt abdominal trauma: case report and review of the literature. Scand. J. Infect. Dis. 39(8), 734-737 (2007).
225. Badenoch PR, Mills RA, Woolley MW et al.: Clostridium novyi keratitis. Br. J. Ophthalmol. 91(5), 691 (2007).
226. Beena VK, Rao S, Subbannayya K et al.: Ocular infection by Clostridium novyi - a case report. Indian J. Pathol. Microbiol. 33(3), 270-271 (1990).
227. Brazier JS, Duerden BI, Hall V et al.: Isolation and identification of Clostridium spp. from infections associated with the injection of drugs: experiences of a microbiological investigation team. J. Med. Microbiol. 51(11), 985-989 (2002).
228. Ebright JR, Pieper B: Skin and soft tissue infections in injection drug users. Infect. Dis. Clin. North Am. 16(3), 697-712 (2002).
229. Finn SP, Leen E, English L et al.: Autopsy findings in an outbreak of severe systemic illness in heroin users following injection site inflammation: an effect of Clostridium novyi exotoxin? Arch. Pathol. Lab. Med. 127(11), 1465-1470 (2003).
230. Ma M, Boyd JT, Trinh HT et al.: Fatal myocarditis due to Clostridium novyi type B in a previously healthy woman: case report and literature review. Scand. J. Infect. Dis. 39(1), 77-80 (2007).
231. Majumdar S, Woodcock S, Cheesbrough J: Severe sepsis following wound infection by an unusual organism-Clostridium novyi. Int. J. Clin. Pract. 58(9), 892-893 (2004).
232. McGuigan C, Roworth M: Clostridium novyi type A infection: a sporadic fatal case. Scand. J. Infect. Dis. 34(3), 209-211 (2002).
233. Vleminckx WG, Diltoer MW, Spapen HD et al.: Splenic abscess with Clostridium novyi bacteraemia and sepsis. Eur. J. Gastroenterol. Hepatol. 9(3), 303-305 (1997).
234. Babenco GO, Joffe N, Tischler AS et al.: Gas-forming clostridial mycotic aneurysm of the abdominal aorta. A case report. Angiology 27(10), 602-609 (1976).
235. Brook I: Clostridial infection in children. J. Med. Microbiol. 42(2), 78-82 (1995).
236. Brook I, Gluck RS: Clostridium paraputrificum sepsis in sickle cell anemia. South. Med. J. 73(12), 1644-1645 (1980).
237. Nachamkin I, DeBlois GE, Dalton HP: Clostridium paraputrificum bacteremia associated with aspiration pneumonia. South. Med. J. 75(8), 1023-1024 (1982).
238. Nerad JL, Pulvirenti JJ: Clostridium paraputrificum bacteremia in a patient with AIDS and Duodenal Kaposi's sarcoma. Clin. Infect. Dis. 23(5), 1183-1184 (1996).
239. Shandera WX, Humphrey RL, Stratton LB: Necrotizing enterocolitis associated with Clostridium paraputrificum septicemia. South. Med. J. 81(2), 283-284 (1988).
240. McClung LS: Human food poisoning due to growth of Clostridium perfringens (C. welchii) in freshly cooked chicken: preliminary note. J. Bacteriol. 50(2), 229-231 (1945).
241. Welch WH, Nuttall GHF: A gas producing bacillus (Bacillus aerogenes capsulatus, nov. spec.) capable of rapid development in the blood vessels after death. Bull. Johns Hopkins Hosp. 3, 81-91 (1892).
242. Larson HE, Borriello SP: Infectious diarrhea due to Clostridium perfringens. J. Infect. Dis. 157(2), 390-391 (1988).
243. Murrell TG, Egerton JR, Rampling A et al.: The ecology and epidemiology of the pig-bel syndrome in man in New Guinea. J. Hyg. (Lond.) 64(3), 375-396 (1966).
244. Zeissler J, Rassfeld-Sternberg L: Enteritis necroticans due to Clostridium welchii type F. Br. Med. J. 1(4597), 267-269 (1949).
245. Langdale LA, Rice CL, Brown N: Emphysematous pyelonephritis in a xanthogranulomatous kidney. An unusual cause of pneumoperitoneum. Arch. Surg. 123(3), 377-379 (1988).
246. Lavigne JP, Bouziges N, Sotto A et al.: Spondylodiscitis due to Clostridium ramosum infection in an immunocompetent elderly patient. J. Clin. Microbiol. 41(5), 2223-2226 (2003).
247. Leal J, Gregson DB, Ross T et al.: Epidemiology of Clostridium species bacteremia in Calgary, Canada, 2000-2006. J. Infect. 57(3), 198-203 (2008).
248. Muakkassa WF, Mohanty PK, Kipreous B et al.: Left ventricular mass with septic (Clostridium ramosum) arterial emboli in a renal allograft patient: report of a case and review of the literature. Transplant Proc. 15(2), 1715-1719 (1983).
249. Nanda N, Voskuhl GW: Lung abscess caused by Clostridium ramosum. J. Okla. State Med. Assoc. 99(4), 158-160 (2006).
250. Turkoglu OF, Solaroglu I, Tun K et al.: Secondary infection of intracranial hydatid cyst with Clostridium ramosum. Childs Nerv. Syst. 21(11), 1004-1007 (2005).
251. van der Vorm ER, von Rosenstiel IA, Spanjaard L et al.: Gas gangrene in an immunocompromised girl due to a Clostridium ramosum infection. Clin. Infect. Dis. 28(4), 923-924 (1999).
252. Hermsen JL, Schurr MJ, Kudsk KA et al.: Phenotyping Clostridium septicum infection: a surgeon's infectious disease. J. Surg. Res. 148(1), 67-76 (2008).
253. Kurtz JE, Claudel L, Collard O et al.: Liver abscess due to Clostridium septicum. A case report and review of the literature. Hepatogastroenterology 52(65), 1557-1558 (2005).
254. Ridgway EJ, Grech ED: Clostridial endocarditis: report of a case caused by Clostridium septicum and review of the literature. J. Infect. 26(3), 309-313 (1993).
255. Seder CW, Kramer M, Long G et al.: Clostridium septicum aortitis: report of two cases and review of the literature. J. Vasc. Surg. 49(5), 1304-1309 (2009).
256. Shetty AK, Heinrich SD, Steele RW: Clostridium septicum osteomyelitis: case report and review. Pediatr. Infect. Dis. J. 17(10), 927-929 (1998).
257. Smith-Slatas CL, Bourque M, Salazar JC: Clostridium septicum infections in children: a case report and review of the literature. Pediatrics 117(4), e796-e805 (2006).
258. Takano H, Taniguchi K, Kuki S et al.: Mycotic aneurysm of the infrarenal abdominal aorta infected by Clostridium septicum: a case report of surgical management and review of the literature. J. Vasc. Surg. 38(4), 847-851 (2003).
259. Abdulla A, Yee L: The clinical spectrum of Clostridium sordellii bacteraemia: two case reports and a review of the literature. J. Clin. Pathol. 53(9), 709-712 (2000).
260. Aldape MJ, Bryant AE, Stevens DL: Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin. Infect. Dis. 43(11), 1436-1446 (2006).
261. Aronoff DM, Ballard JD: Clostridium sordellii toxic shock syndrome. Lancet Infect. Dis. 9(12), 725-726 (2009).
262. Barnes P, Leedom JM: Infective endocarditis due to Clostridium sordellii. Am. J. Med. 83(3), 605 (1987).
263. Dunbar NM, Harruff RC: Necrotizing fasciitis: manifestations, microbiology and connection with black tar heroin. J. Forensic Sci. 52(4), 920-923 (2007).
264. File TM Jr, Fass RJ, Perkins RL: Pneumonia and empyema caused by Clostridium sordellii. Am. J. Med. Sci. 274(2), 211-212 (1977).
265. Babudieri S, Borriello SP, Pantosti A et al.: Diarrhoea associated with toxigenic Clostridium spiroforme. J. Infect. 12(3), 278-279 (1986).
266. Fujitani S, Liu CX, Finegold SM et al.: Clostridium tertium isolated from gas gangrene wound; misidentified as Lactobacillus spp initially due to aerotolerant feature. Anaerobe 13(3-4), 161-165 (2007).
267. Gredlein CM, Silverman ML, Downey MS: Polymicrobial septic arthritis due to Clostridium species: case report and review. Clin. Infect. Dis. 30(3), 590-594 (2000).
268. Lew JF, Wiedermann BL, Sneed J et al.: Aerotolerant Clostridium tertium brain abscess following a lawn dart injury. J. Clin. Microbiol. 28(9), 2127-2129 (1990).
269. Miller DL, Brazer S, Murdoch D et al.: Significance of Clostridium tertium bacteremia in neutropenic and nonneutropenic patients: review of 32 cases. Clin. Infect. Dis. 32(6), 975-978 (2001).
270. Brook I: Current concepts in the management of Clostridium tetani infection. Expert Rev. Anti Infect. Ther. 6(3), 327-336 (2008).
271. Carle A, Rattone G: Studio esperimentale sull 'eziologia del tetano. G. Accad. Ned. Torino 32, 174-180 (1884).
272. Paredes-Sabja D, Torres JA, Setlow P et al.: Clostridium perfringens spore germination: characterization of germinants and their receptors. J. Bacteriol. 190(4), 1190-1201 (2008).
273. Moir A: How do spores germinate? J. Appl. Microbiol. 101(3), 526-530 (2006).
274. van der Voort M, Garcia D, Moezelaar R et al.: Germinant receptor diversity and germination responses of four strains of the Bacillus cereus group. Int. J. Food Microbiol. 139(1-2), 108-115 (2010).
275. Paredes-Sabja D, Setlow P, Sarker MR: Role of GerKB in germination and outgrowth of Clostridium perfringens spores. Appl. Environ. Microbiol. 75(11), 3813-3817 (2009).